July 27, 2016
ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, reported operating results for the second quarter of 2016 as follows:
Quarterly Highlights:
- Achieved worldwide revenues of $67.6 million, exceeding company revenue guidance of $66 million to $67 million.
- Achieved worldwide direct revenues of $39.6 million, a 16 percent increase over the second quarter of 2015.
- Achieved U.S. direct spine revenues of $17.6 million, a 25 percent increase over the second quarter of 2015.
- Achieved direct international revenues of $5.7 million, a 27 percent increase over the second quarter of 2015.
- Achieved U.S. direct cardiothoracic revenues of $2.9 million, a 31 percent increase over the second quarter of 2015.
- Focused products, which include map3® Cellular Allogeneic Bone Graft, nanOss® Advanced Bone Graft Substitute and the company’s U.S. direct surgical specialties portfolio, grew 54 percent compared to the second quarter of 2015.
- Announced first peer-reviewed, published pre-clinical study comparing multipotent adult progenitor cells (MAPCs) to mensenchymal stem cells (MSCs) in bone healing.
Worldwide revenues were $67.6 million for the second quarter of 2016 compared to revenues of $71.6 million for the second quarter of 2015. Domestic revenues were $61 million for the second quarter of 2016 compared to revenues of $66 million for the second quarter of 2015. International revenues were $6.6 million for the second quarter of 2016, compared to revenues of $5.6 million for the second quarter of 2015. On a constant currency basis, international revenues for the second quarter of 2016 increased 16 percent compared to the second quarter of 2015.
“Our direct business continued to perform well in the quarter; however, this was offset by declines in our commercial business that were greater than we anticipated because of lower orders associated with consolidation among some of our commercial distributors,” said Brian K. Hutchison, president and chief executive officer. “While revenues were slightly above the top end of our guidance for the quarter, the reduced outlook for the commercial business for the remainder of the year required a slow down in manufacturing production resulting in a lower-than-expected gross margin, which negatively impacted our EPS.”
For the second quarter of 2016, the company reported net loss applicable to common shares of $3.2 million and net loss per fully diluted common share of $0.05, based on 58.2 million fully diluted shares outstanding, compared to net income applicable to common shares of $2.7 million and net income per fully diluted common share of $0.05 for the second quarter of 2015, based on 58.8 million fully diluted shares outstanding. On an adjusted basis, excluding pre-tax charges of $2.4 million for contested proxy expenses, pre-tax restructuring charges of $1.1 million for closure of a French distribution and tissue procurement office, and pre-tax severance charges of $0.7 million, adjusted net loss applicable to common shares was $0.2 million and adjusted net loss per fully diluted common share was $0.00, based on 58.2 million fully diluted shares outstanding.
Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA), as detailed in the reconciliation provided later in this release, was $6.4 million for the second quarter of 2016 (10 percent of second quarter 2016 revenues) compared to $10.8 million for the second quarter of 2015 (15 percent of second quarter 2015 revenues). The decline was principally a result of lower revenues combined with increased investments in research and development and the development of our international sales network.
Strategic Business Review
The company also announced today that its management and board of directors are launching a comprehensive strategic review of the company’s business lines and operations to leverage the company’s leading expertise, technology and products and identify additional opportunities to increase stockholder value. The company intends to engage a management consulting firm to assist with this review.
“Over the last several years RTI has pursued an aggressive and transformational strategy to grow the company and improve profitability,” Hutchison said. “We have made extensive investments in our higher margin direct businesses and broadened the implant portfolio to include metals and synthetics, while controlling our operating costs. The results of the strategy have been encouraging, but we remain focused on exploring new opportunities to grow our company and enhance performance. The strategic review of our businesses and operations on which we are embarking is the logical next step to look for additional ways to adapt to our changing industry and health care paradigm so that we can generate increased value for stockholders.”
Fiscal 2016 Outlook
Based on the outlook for the commercial business for the remainder of the year, the company now expects that full year revenue for 2016 will range from $274 million to $280 million, as compared to prior guidance of $282 million to $290 million. The company expects full year direct revenue to grow in the range of 16 percent to 17 percent as compared to the previous range of 16 percent to18 percent and full year commercial and other revenue to decline in the range of 18 percent to 21 percent as compared to the previous range of 13 percent to 16 percent. As a result of the lower revenue guidance, the company now expects full year net income per fully diluted common share for 2016 will range from $0.03 to $0.06, based on 58.5 million fully diluted shares outstanding, as compared to prior guidance of $0.18 to $0.21. Excluding the previously mentioned contested proxy expenses, restructuring charges, and severance charges, adjusted full year 2016 net income per fully diluted common share is expected to range from $0.09 to $0.12, based on 58.5 million fully diluted shares outstanding. The net income and adjusted net income guidance excludes any costs incurred as a result of the upcoming strategic review.
Conference Call
RTI will host a conference call and simultaneous audio webcast to discuss the second quarter results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on the RTI website following the call.
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.
Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.
| RTI SURGICAL, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (Unaudited, in thousands, except share and per share data) |
|||||||||||||||||||||||
| For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
||||||||||||||||||||||
| 2016 | 2015 | 2016 | 2015 | ||||||||||||||||||||
| Revenues | $ | 67,620 | $ | 71,609 | $ | 134,971 | $ | 139,643 | |||||||||||||||
| Costs of processing and distribution | 33,671 | 34,406 | 64,997 | 65,441 | |||||||||||||||||||
| Gross profit | 33,949 | 37,203 | 69,974 | 74,202 | |||||||||||||||||||
| Expenses: | |||||||||||||||||||||||
| Marketing, general and administrative | 28,402 | 27,369 | 55,954 | 54,624 | |||||||||||||||||||
| Research and development | 4,084 | 4,119 | 8,245 | 7,699 | |||||||||||||||||||
| Restructuring charges | 1,107 | – | 1,107 | – | |||||||||||||||||||
| Contested proxy expenses | 2,372 | – | 2,680 | – | |||||||||||||||||||
| Severance charges | 711 | – | 711 | – | |||||||||||||||||||
| Total operating expenses | 36,676 | 31,488 | 68,697 | 62,323 | |||||||||||||||||||
| Operating (loss) income | (2,727 | ) | 5,715 | 1,277 | 11,879 | ||||||||||||||||||
| Total other expense – net | (424 | ) | (287 | ) | (738 | ) | (581 | ) | |||||||||||||||
| (Loss) income before income tax provision | (3,151 | ) | 5,428 | 539 | 11,298 | ||||||||||||||||||
| Income tax benefit (provision) | 859 | (1,923 | ) | (430 | ) | (4,051 | ) | ||||||||||||||||
| Net (loss) income | (2,292 | ) | 3,505 | 109 | 7,247 | ||||||||||||||||||
| Convertible preferred dividend | (870 | ) | (820 | ) | (1,728 | ) | (1,628 | ) | |||||||||||||||
| Net (loss) income applicable to common shares | $ | (3,162 | ) | $ | 2,685 | $ | (1,619 | ) | $ | 5,619 | |||||||||||||
| Net (loss) income per common share – basic | $ | (0.05 | ) | $ | 0.05 | $ | (0.03 | ) | $ | 0.10 | |||||||||||||
| Net (loss) income per common share – diluted | $ | (0.05 | ) | $ | 0.05 | $ | (0.03 | ) | $ | 0.10 | |||||||||||||
| Weighted average shares outstanding – basic | 58,215,477 | 57,523,447 | 58,065,185 | 57,301,204 | |||||||||||||||||||
| Weighted average shares outstanding – diluted | 58,215,477 | 58,755,954 | 58,065,185 | 58,342,045 | |||||||||||||||||||
| RTI SURGICAL, INC. AND SUBSIDIARIES Reconciliation of Net (Loss) Income Applicable to Commons Shares to Adjusted EBITDA (Unaudited, in thousands) |
|||||||||||||||||||||||
| For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
||||||||||||||||||||||
| 2016 | 2015 | 2016 | 2015 | ||||||||||||||||||||
| Net (loss) income | $ | (3,162 | ) | $ | 2,685 | $ | (1,619 | ) | $ | 5,619 | |||||||||||||
| Interest expense, net | 386 | 326 | 746 | 642 | |||||||||||||||||||
| (Benefit) provision for income taxes | (859 | ) | 1,923 | 430 | 4,051 | ||||||||||||||||||
| Depreciation | 3,454 | 3,257 | 6,836 | 6,201 | |||||||||||||||||||
| Amortization of intangible assets | 930 | 1,123 | 1,858 | 2,145 | |||||||||||||||||||
| EBITDA | 749 | 9,314 | 8,251 | 18,658 | |||||||||||||||||||
| Reconciling items for Adjusted EBITDA | |||||||||||||||||||||||
| Preferred dividend | 870 | 820 | 1,728 | 1,628 | |||||||||||||||||||
| Non-cash stock based compensation | 600 | 680 | 1,100 | 1,253 | |||||||||||||||||||
| Foreign exchange (loss) gain | 38 | (39 | ) | (8 | ) | (61 | ) | ||||||||||||||||
| Other reconciling items(1) | |||||||||||||||||||||||
| Restructuring charges | 1,107 | – | 1,107 | – | |||||||||||||||||||
| Contested proxy expenses | 2,372 | – | 2,680 | – | |||||||||||||||||||
| Severance charges | 711 | – | 711 | – | |||||||||||||||||||
| Adjusted EBITDA | $ | 6,447 | $ | 10,775 | $ | 15,569 | $ | 21,478 | |||||||||||||||
| Adjusted EBITDA as a percent of revenues | 10 | % | 15 | % | 12 | % | 15 | % | |||||||||||||||
| (1) See explanations in Use of Non-GAAP Financial Measures section later in this release. | |||||||||||||||||||||||
| RTI SURGICAL, INC. AND SUBSIDIARIES Reconciliation of Net (Loss) Income Applicable to Common Shares and Net (Loss) Income Per Diluted Share to Adjusted Net (Loss) Income Applicable to Common Shares and Adjusted Net (Loss) Income Per Diluted Share (Unaudited, in thousands, except per share data) |
||||||||||||||
| For the Three Months Ended | ||||||||||||||
| June 30, 2016 | June 30, 2015 | |||||||||||||
| Net Income Applicable to Common Shares |
Amount per Diluted Share |
Net Income Applicable to Common Shares |
Amount per Diluted Share |
|||||||||||
| As reported | $ | (3,162 | ) | $ | (0.05 | ) | $ | 2,685 | $ | 0.05 | ||||
| Restructuring charges, net of tax effect (1) | 1,050 | $ | 0.02 | – | – | |||||||||
| Contested proxy expenses, net of tax effect (2) | 1,464 | $ | 0.03 | – | – | |||||||||
| Severance charges, net of tax effect (3) | 439 | $ | 0.01 | – | – | |||||||||
| Adjusted | $ | (209 | ) | $ | (0.00 | ) | $ | 2,685 | $ | 0.05 | ||||
| For the Six Months Ended | ||||||||||||||
| June 30, 2016 | June 30, 2015 | |||||||||||||
| Net Income Applicable to Common Shares |
Amount per Diluted Share |
Net Loss Applicable to Common Shares |
Amount per Diluted Share |
|||||||||||
| As reported | $ | (1,619 | ) | $ | (0.03 | ) | $ | 5,619 | $ | 0.10 | ||||
| Restructuring charges, net of tax effect (1) | 1,050 | 0.02 | – | – | ||||||||||
| Contested proxy expenses, net of tax effect (4) | 1,654 | 0.03 | – | – | ||||||||||
| Severance charges, net of tax effect (3) | 439 | 0.01 | – | – | ||||||||||
| Adjusted | $ | 1,524 | $ | 0.03 | $ | 5,619 | $ | 0.10 | ||||||
| Note: Amounts may not foot due to rounding. | ||||||||||||||
| Footnotes: | 2016 | |||||||||||||
| (1) Restructuring charges, net of tax effect, as follows: | ||||||||||||||
| Restructuring charges | $ | 1,107 | ||||||||||||
| Tax effect on Restructuring charges | (57 | ) | ||||||||||||
| Restructuring charges, net of tax effect | $ | 1,050 | ||||||||||||
| (2) Contested proxy expenses, net of tax effect, as follows: | ||||||||||||||
| Contested proxy expenses | $ | 2,372 | ||||||||||||
| Tax effect on contested proxy expenses | (908 | ) | ||||||||||||
| Contested proxy expenses, net of tax effect | $ | 1,464 | ||||||||||||
| (3) Severance charges, net of tax effect, as follows: | ||||||||||||||
| Severance charges | $ | 711 | ||||||||||||
| Tax effect on Severance charges | (272 | ) | ||||||||||||
| Severance charges, net of tax effect | $ | 439 | ||||||||||||
| (4) Contested proxy expenses, net of tax effect, as follows: | ||||||||||||||
| Contested proxy expenses | $ | 2,680 | ||||||||||||
| Tax effect on contested proxy expenses | (1,026 | ) | ||||||||||||
| Contested proxy expenses, net of tax effect | $ | 1,654 | ||||||||||||
Fiscal 2016 Outlook
Full year net income per fully diluted common share is expected to be in the range of $0.03 to $0.06, based on 58.5 million fully diluted shares outstanding. Excluding contested proxy expenses, restructuring charges and severance charges taken in the second quarter of 2016, full year net income per fully diluted common share is expected to be in the range of $0.09 to $0.12.
| RTI SURGICAL, INC. AND SUBSIDIARIES Reconciliation of GAAP Guidance Net Income Per Common Share – Diluted to Adjusted Non-GAAP Guidance Net Income Per Common Share – Diluted (Unaudited) |
|||
| Twelve Months Ended | |||
| December 31, 2016 | |||
| $ Amount per Common Share – Diluted |
|||
| GAAP Guidance net income per common share – diluted | $ 0.03 – 0.06 | ||
| Restructuring charges, net of tax effect (1) | 0.02 | ||
| Contested proxy expenses, net of tax effect (2) | 0.03 | ||
| Severance charges, net of tax effect (3) | 0.01 | ||
| Adjusted non-GAAP guidance net income per common share – diluted | $ 0.09 – 0.12 | ||
Use of Non-GAAP Financial Measures
To supplement the Company’s condensed consolidated financial statements presented on a GAAP basis, the Company discloses adjusted EBITDA, a non-GAAP financial measure that excludes certain amounts. This non-GAAP financial measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States. A reconciliation of the non-GAAP financial measure to the corresponding GAAP measure is included in the table above.
The following is an explanation of the adjustment that management excluded as part of adjusted measures for the three and six month periods ended June 30, 2016 as well as the reason for excluding the individual items:
(1) Restructuring charges – This adjustment represents the closure of our French distribution and tissue procurement office. Management removes the amount of these expenses from our operating results to supplement a comparison to our past operating performance.
(2) Contested proxy expenses – This adjustment represent charges relating to contested proxy expenses. Management removes the amount of these expenses from our operating results to supplement a comparison to our past operating performance.
(3) Severance charges – This adjustment represents charges relating to the termination of former employees. Management removes the amount of these expenses from our operating results to supplement a comparison to our past operating performance.
Material Limitations Associated with the Use of Non-GAAP Financial Measures
Adjusted EBITDA should not be considered in isolation, or as a replacement for GAAP measures.
Usefulness of Non-GAAP Financial Measures to Investors
The Company believes that presenting adjusted EBITDA in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making which excludes the restructuring charges, contested proxy expenses and severance charges. The Company further believes that providing this information better enables the Company’s investors to understand the Company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.
| RTI SURGICAL, INC. AND SUBSIDIARIES Condensed Consolidated Revenues (Unaudited, in thousands) |
|||||||||||||||
| For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
||||||||||||||
| 2016 | 2015 | 2016 | 2015 | ||||||||||||
| Revenues: | |||||||||||||||
| Spine | $ | 17,645 | $ | 14,061 | $ | 34,739 | $ | 28,701 | |||||||
| Sports medicine and orthopedics | 12,562 | 12,796 | 25,082 | 25,772 | |||||||||||
| Surgical specialties | 802 | 684 | 1,817 | 1,334 | |||||||||||
| Cardiothoracic | 2,905 | 2,217 | 5,439 | 4,178 | |||||||||||
| International | 5,663 | 4,474 | 11,180 | 9,145 | |||||||||||
| Subtotal direct | 39,577 | 34,232 | 78,257 | 69,130 | |||||||||||
| Global commercial | 24,769 | 33,960 | 50,099 | 62,879 | |||||||||||
| Other revenues | 3,274 | 3,417 | 6,615 | 7,634 | |||||||||||
| Total revenues | $ | 67,620 | $ | 71,609 | $ | 134,971 | $ | 139,643 | |||||||
| Domestic revenues | 61,049 | 66,017 | 122,233 | 128,705 | |||||||||||
| International revenues | 6,571 | 5,592 | 12,738 | 10,938 | |||||||||||
| Total revenues | $ | 67,620 | $ | 71,609 | $ | 134,971 | $ | 139,643 | |||||||
| RTI SURGICAL, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited, in thousands) |
|||||||||||||||
| June 30, 2016 |
December 31, 2015 |
||||||||||||||
| Assets | |||||||||||||||
| Cash and cash equivalents | $ | 12,754 | $ | 12,614 | |||||||||||
| Accounts receivable – net | 37,263 | 47,243 | |||||||||||||
| Inventories – net | 121,035 | 118,673 | |||||||||||||
| Prepaid and other current assets | 13,777 | 13,184 | |||||||||||||
| Total current assets | 184,829 | 191,714 | |||||||||||||
| Property, plant and equipment – net | 88,201 | 84,992 | |||||||||||||
| Goodwill | 54,887 | 54,887 | |||||||||||||
| Other assets – net | 48,359 | 49,069 | |||||||||||||
| Total assets | $ | 376,276 | $ | 380,662 | |||||||||||
| Liabilities and Stockholders’ Equity | |||||||||||||||
| Accounts payable | $ | 25,760 | $ | 20,446 | |||||||||||
| Accrued expenses and other current liabilities | 25,245 | 33,474 | |||||||||||||
| Current portion of long-term obligations | 4,995 | 5,853 | |||||||||||||
| Total current liabilities | 56,000 | 59,773 | |||||||||||||
| Deferred revenue | 8,896 | 9,354 | |||||||||||||
| Long-term liabilities | 72,700 | 73,856 | |||||||||||||
| Total liabilities | 137,596 | 142,983 | |||||||||||||
| Preferred stock, including accrued dividends | 58,143 | 56,323 | |||||||||||||
| Stockholders’ equity: | |||||||||||||||
| Common stock and additional paid-in capital | 416,503 | 417,337 | |||||||||||||
| Accumulated other comprehensive loss | (7,136 | ) | (7,042 | ) | |||||||||||
| Accumulated deficit | (228,830 | ) | (228,939 | ) | |||||||||||
| Total stockholders’ equity | 180,537 | 181,356 | |||||||||||||
| Total liabilities and stockholders’ equity | $ | 376,276 | $ | 380,662 | |||||||||||
| RTI SURGICAL, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (Unaudited, in thousands) |
||||||||||||||||
| For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
|||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||||
| Net (loss) income | $ | (2,292 | ) | $ | 3,505 | $ | 109 | $ | 7,247 | |||||||
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | ||||||||||||||||
| Depreciation and amortization expense | 4,384 | 4,380 | 8,694 | 8,346 | ||||||||||||
| Stock-based compensation | 600 | 680 | 1,100 | 1,253 | ||||||||||||
| Amortization of deferred revenue | (1,217 | ) | (1,159 | ) | (2,434 | ) | (3,905 | ) | ||||||||
| Other items to reconcile to net cash provided by operating activities | 5,311 | (1,695 | ) | 5,740 | (6,224 | ) | ||||||||||
| Net cash provided by operating activities | 6,786 | 5,711 | 13,209 | 6,717 | ||||||||||||
| Cash flows from investing activities: | ||||||||||||||||
| Purchases of property, plant and equipment | (4,766 | ) | (4,312 | ) | (9,403 | ) | (8,577 | ) | ||||||||
| Patent and acquired intangible asset costs | (195 | ) | (94 | ) | (1,391 | ) | (116 | ) | ||||||||
| Net cash used in investing activities | (4,961 | ) | (4,406 | ) | (10,794 | ) | (8,693 | ) | ||||||||
| Cash flows from financing activities: | ||||||||||||||||
| Proceeds from long-term obligations | 4,000 | – | 7,000 | – | ||||||||||||
| Net (payments) proceeds from short-term obligations | (600 | ) | (162 | ) | (849 | ) | 348 | |||||||||
| Payments on long-term obligations | (4,166 | ) | (1,513 | ) | (8,299 | ) | (3,026 | ) | ||||||||
| Other financing activities | 14 | 1,142 | (94 | ) | 1,696 | |||||||||||
| Net cash used in financing activities | (752 | ) | (533 | ) | (2,242 | ) | (982 | ) | ||||||||
| Effect of exchange rate changes on cash and cash equivalents | (47 | ) | 23 | (33 | ) | (46 | ) | |||||||||
| Net increase (decrease) in cash and cash equivalents | 1,026 | 795 | 140 | (3,004 | ) | |||||||||||
| Cash and cash equivalents, beginning of period | 11,728 | 11,904 | 12,614 | 15,703 | ||||||||||||
| Cash and cash equivalents, end of period | $ | 12,754 | $ | 12,699 | $ | 12,754 | $ | 12,699 | ||||||||
- Contacts
- RTI Surgical Inc.
Robert Jordheim, 386-418-8888
Executive Vice President,
Chief Financial Officer
rjordheim@rtix.com
or
Wendy Crites Wacker, APR, 386-418-8888
Vice President, Global Communications
wwacker@rtix.com
